Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)’. The study aims to evaluate the efficacy of combining tarlatamab with durvalumab compared to using durvalumab alone in improving overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC).
The study tests two interventions: tarlatamab, an experimental drug given every two weeks, and durvalumab, administered every four weeks. The combination aims to enhance treatment outcomes for ES-SCLC patients.
This interventional study is randomized with a parallel assignment model, focusing on treatment as its primary purpose. It is open-label, meaning no masking is involved, allowing both researchers and participants to know which treatment is being administered.
The study began on June 5, 2024, with primary completion expected in the future. The latest update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact Amgen’s stock performance and investor sentiment, especially if the combination therapy proves more effective than the current standard. It also positions Amgen as a competitive player in the oncology market, potentially influencing industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.